Calcilytix Therapeutics, Inc., A Bridgebio Company
Clinical trials sponsored by Calcilytix Therapeutics, Inc., A Bridgebio Company, explained in plain language.
A biotech company developing therapies for calcification-related diseases, owned by BridgeBio.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New drug aims to fix calcium levels in rare genetic disease
Disease control OngoingThis study tests a new drug called encaleret against usual treatments for people with a rare genetic condition called autosomal dominant hypocalcemia type 1 (ADH1), which causes low blood calcium and high urine calcium. About 67 participants will receive either encaleret or stand…
Phase 3 • Sponsor: Calcilytix Therapeutics, Inc., a BridgeBio company • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New study monitors rare calcium disorder to better understand its long-term effects
Knowledge-focused OngoingThis study is for people with autosomal dominant hypocalcemia types 1 or 2, rare genetic conditions that cause low blood calcium. Researchers will collect past and future health data from 95 participants to learn how the disease changes over time. The goal is to better understand…
Sponsor: Calcilytix Therapeutics, Inc., a BridgeBio company • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC